DOJ to Aid in Whistleblower Case Against Pfizer, But Not Intervene

The Justice Department has stated it will not be intervening in a whistleblower lawsuit against New York City-based Pfizer but has filed a statement of interest to aid the whistleblower after Pfizer filed a motion to dismiss the case, according to an AboutLawsuits report.

Advertisement

Jesse Polansky, a former Pfizer executive, filed a lawsuit against the company accusing it of misleading physicians about its cholesterol drug Lipitor through its use of educational programs and product labeling as well as manipulating federal cholesterol regulations in order to boost sales of the drug.  Mr. Polansky specifically claimed sales of Lipitor increased 18 percent because Pfizer had illegally marketed off-label use of the drug, causing false claims to be submitted to federal healthcare programs.

Mr. Polansky also accuses Pfizer of being involved in an alleged kickback scheme, according to the report. The report does not disclose any details about the alleged kickbacks scheme or what off-label uses were promoted.

Read the AboutLawsuits report about the Pfizer’s alleged fraud.

Read other coverage about Pfizer:

Justice Department Files to Intervene in Whistleblower Kickback Case Against Pfizer

5 Antikickback Cases Making Headlines

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.